Results 11 to 20 of about 8,704 (178)

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus

Бюллетень сибирской медицины, 2021
Aim. To study the effect of eplerenone on the activity of free radical oxidation and renal function in rats with experimental diabetes mellitus induced by streptozotocin.Materials and methods. Experiments were carried out on 36 male Wistar rats. Diabetes
A. Yu. Zharikov, S. O. Filinova, O. N. Mazko, O. G. Makarova, I. P. Bobrov, V. M. Bryukhanov   +5 more
doaj   +1 more source

Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats

Clinical and Experimental Hypertension, 2020
Evidence indicates that renin-angiotensin-aldosterone system (RAS) inhibitors can protect the brain in Alzheimer’s disease and Parkinson’s disease.
Xue Wang, Yuhai Zhu, Shuanglin Wang, Zhuoqun Wang, Haonan Sun, Yujie He, Wei Yao   +6 more
doaj   +1 more source

Possible dose-dependent effect of eplerenone on intraocular pressure

Indian Journal of Ophthalmology, 2023
Purpose: Intraocular pressure (IOP) is the main modifiable risk factor for glaucoma. Current therapies target the anterior outflow of aqueous humor or its production. This study aims to demonstrate eplerenone could reduce IOP through a possible posterior
Seyedeh Mehrsa Sadat Razavi, Ramin Daneshvar   +1 more
doaj   +1 more source

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)

Лечащий Врач, 2023
The article focuses on the negative role of hyperaldosteronism in cardiovascular diseases and the possibility of its control when using a selective mineralocorticoid receptor antagonist – eplerenone.
A. G. Evdokimova, R. I. Stryuk, V. V. Evdokimov, A. K. Kaptaeva   +3 more
doaj   +1 more source

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE

Кардиоваскулярная терапия и профилактика, 2015
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic
Yu. M. Lopatin, E. Yu. Lopatina
doaj   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome. [PDF]

Diabetes Obes Metab
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Zeitler E, Klein KR, Lingvay I, Pick A, Billings LK.   +4 more
europepmc   +2 more sources

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE

Рациональная фармакотерапия в кардиологии, 2015
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
B. B. Gegenava, O. M. Drapkina
doaj   +3 more sources

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. [PDF]

PLoS ONE, 2011
Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD).
Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper   +4 more
doaj   +1 more source

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

Frontiers in Pharmacology, 2013
The mineralocorticoid receptor (MR) antagonists PF 03882845 and eplerenone were evaluated for renal protection against aldosterone mediated renal disease in uninephrectomized Sprague Dawley (SD) rats maintained on a high salt diet and receiving ...
Stephen eOrena, Stephen eOrena, Tristan eMaurer, Rena eEudy, Rena eEudy, Li eShe, Darla eDash, Paula eLoria, Mary Ellen eBanker, Vincent eBernardo, Meera eTugnait, Carlin eOkerberg, Jessie eQian, Carine M Boustany-Kari, Carine M Boustany-Kari   +14 more
doaj   +1 more source

Oral eplerenone for the management of chronic central serous chorioretinopathy [PDF]

International Journal of Ophthalmology, 2015
AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR).
Rishi P Singh, Jonathan E Sears, Rumneek Bedi, Andrew P Schachat, Justis P Ehlers, Peter K Kaiser   +5 more
doaj   +1 more source